News Coverage

CD24Fc protects against viral pneumonia in simian immunodeficiency virus-infected Chinese rhesus monkeys. 

Tian R, Zhang M, Liu M, Fang X, Li D, Zhang L, Zheng P, Zheng Y & Liu Y. 2020.

Cellular & Molecular Immunology 17: 887-888.


Liposomal formulation of HIF-1α inhibitor echinomycin eliminates established metastases of triple-negative breast cancer. 

Bailey CM, Liu Y, Peng G, Zhang H, He M, Sun D, Zheng P, Liu Y, Wang Y.

Nanomedicine. 2020 Jul 30:102278. doi: 10.1016/j.nano.2020.


Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1α with echinomycin. 

Wang Y, Liu Y, Bailey C, Zhang H, He M, Sun D, Zhang P, Parkin B, Baer MR, Zheng P, Malek SN, Liu Y

Oncogene. 2020 Apr;39(14):3015-3027. doi: 10.1038/s41388-020-1201-z. Epub 2020 Feb 15.


Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy.

Zhang Y, Du X, Liu M, Tang F, Zhang P, Ai C, Fields JK, Sundberg EJ, Latinovic OS, Devenport M, Zheng P, Liu Y.

Cell Res. 2019 Aug;29(8):609-627. doi: 10.1038/s41422-019-0184-1. Epub 2019 Jul 2.


How Does an Anti-CTLA-4 Antibody Promote Cancer Immunity?

Liu Y, Zheng P.

Trends Immunol. 2018 Dec;39(12):953-956. doi: 10.1016/


CD24 and Fc fusion protein protects SIVmac239-infected Chinese rhesus macaque against progression to AIDS.

Tian RR, Zhang MX, Zhang LT, Zhang P, Ma JP, Liu M, Devenport M, Zheng P, Zhang XL, Lian XD, Ye M, Zheng HY, Pang W, Zhang GH, Zhang LG, Liu Y, Zheng YT.

Antiviral Res. 2018 Sep;157:9-17.


Uncoupling Therapeutic from Immunotherapy-related Adverse Effects for Safer and Effective Anti-CTLA-4 Antibodies in CTLA4 Humanized Mice. 

Du X, Liu M, Su J, Zhang P, Tang F, Ye P, Devenport M, Wang X, Zhang Y, Liu Y, Zheng P.

Cell Res. 2018 Apr;28(4):433-447. doi: 10.1038/s41422-018-0012-z. Epub 2018 Feb 20.


A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy. 

Du X, Tang F, Liu M, Su J, Zhang Y, Wu W, Devenport M, Lazarski CA, Zhang P, Wang X, Ye P, Wang C, Hwang E, Zhu T, Xu T, Zheng P, Liu Y.

Cell Res. 2018 Apr;28(4):416-432. doi: 10.1038/s41422-018-0011-0. Epub 2018 Feb 22.


Siglec-G-CD24 axis controls the severity of graft-versus-host disease in mice. 

Toubai T, Hou G, Mathewson N, Liu C, Wang Y, Oravecz-Wilson K, et al.

Blood. 2014;123(22):3512-23.


Siglec-G/10 in self-nonself discrimination of innate and adaptive immunity.

Chen GY, Brown NK, Zheng P, Liu Y.

Glycobiology. 2014 Sep;24(9):800-6. doi: 10.1093/glycob/cwu068. Epub 2014 Jul 4.


Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells.

Wang Y, Liu Y, Tang F, Bernot KM, Schore R, Marcucci G, Caligiuri MA, Zheng P, Liu Y.

Blood. 2014 Aug 14;124(7):1127-35. doi: 10.1182/blood-2013-12-544221.


A hypermorphic SP1-binding CD24 variant associates with risk and progression of multiple sclerosis.

Lizhong Wang, Runhua Liu, Dongling Li, Shili Lin, Xianfeng Fang, et al.

Am J Transl Res. 2012; 4(3): 347–356.


Amelioration of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG interaction.

Chen GY, Chen X, King S, Cavassani KA, Cheng J, Zheng X, Cao H, Yu H, et al.
Nat Biotechnol. 2011 May;29(5):428-35.


Targeting HIF1α eliminates cancer stem cells in hematological malignancies.

Wang Y, Liu Y, Malek SN, Zheng P, Liu Y.

Cell Stem Cell. 2011 Apr 8;8(4):399-411. doi: 10.1016/j.stem.2011.02.006.


Sialoside-based pattern recognitions discriminating infections from tissue injuries.

Liu Y, Chen GY, Zheng P.

Curr Opin Immunol. 2011 Feb;23(1):41-5. doi: 10.1016/j.coi.2010.10.004. Epub 2011 Jan 3.


CD24 and Siglec-10 Selectively Repress Tissue Damage-Induced Immune Responses.

Chen GY, Tang J, Zheng P, Liu Y.

Science. 2009;323:1722-5.


CD24-Siglec G/10 discriminates danger- from pathogen-associated molecular patterns.

Liu Y, Chen GY, Zheng P.

Trends Immunol. 2009 Dec;30(12):557-61. doi: 10.1016/ Epub 2009 Sep 26.


A dinucleotide deletion in CD24 confers protection against autoimmune diseases.

Wang L, Lin S, Rammohan KW, Liu Z, Liu JQ, Liu RH, Guinther N, et al.

PLoS Genet. 2007 Apr 6;3(4):e49.


Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity.

Kocak E, Lute K, Chang X, May KF, Jr., Exten KR, Zhang H, et al.

Cancer Res. 2006;66(14):7276-84. Epub 2006/07/20. doi: 10.1158/0008-5472.CAN-05-2128. PubMed PMID: 16849577.


Human CTLA-4-knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies.

Lute KD, May KF, Lu P, Zhang H, Kocak E, Mosinger B, et al.

Blood. 2005. PubMed PMID: 16037385.


Anti-human CTLA-4 monoclonal antibody promotes T cell expansion and immunity in a hu-PBL-SCID model: a new method for preclinical screening of costimulatory monoclonal antibodies.

May KF, Roychowdhury S, Bhatt D, Kocak E, Bai XF, Liu JQ, et al.

Blood. 2005;105:1114-20. PubMed PMID: 15486062.


CD24 is a genetic modifier for risk and progression of multiple sclerosis.

Zhou Q, Rammohan K, Lin S, Robinson N, Li O, Liu X, Bai XF, Yin L, et al.

Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15041-6.

More in this category: « News Coverage Careers »

About Us

Based in Rockville, Maryland, OncoImmune is a
privately-held, clinical-stage biopharmaceutical
company that is actively engaged in the discovery
and development of biopharmaceuticals for the
treatment of cancer and autoimmune disease.

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.